Liraglutide Injection
Product Images NDC 0480-3667

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 0480-3667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton_2_pens (Carton 2 Pens)

Packaging label for Liraglutide injection 18 mg/3 mL (6 mg/mL) subcutaneous injection by Teva Pharmaceuticals USA, Inc. The carton contains 2 prefilled injection pens for single-patient use only. The label includes dosage strengths and storage instructions, and indicates the product is manufactured by Novo Nordisk A/S in Denmark.*

FDA Label Image

Carton_3_pens (Carton 3 Pens)

Liraglutide injection 18 mg/3 mL (6 mg/mL) subcutaneous injectable solution in a box containing 3 prefilled pens. The label highlights single-patient use, refrigeration requirements, and manufacturer information for Teva Pharmaceuticals USA, Inc. The packaging includes barcode, usage instructions, and a graphic of the blue Liraglutide pens.*

FDA Label Image

Figure-1 (Figure 1)

Chemical structure diagram of liraglutide showing its amino acid sequence arranged in a loop with labeled residues including His, Ala, Glu, and others. The structure highlights a C-16 fatty acid (palmitoyl) attached to a Glu residue and features an arrow indicating a connection involving Arg and Lys residues. The figure is titled 'Figure 1. Structural Formula of Liraglutide.'*

FDA Label Image

Figure-2 (Figure 2)

A line graph comparing ISR (pmol/kg/min) versus plasma glucose (mg/dL) for Liraglutide and placebo. The graph shows Liraglutide data points as black diamonds and placebo as gray triangles, illustrating increasing ISR values with higher plasma glucose levels for both groups, with Liraglutide demonstrating consistently higher ISR across the range.*

FDA Label Image

Figure_3 (Figure 3)

A line graph comparing mean HbA1c (%) levels over 52 weeks among three groups: Glimepiride, Liraglutide 1.2 mg, and Liraglutide 1.8 mg. The x-axis represents time in weeks, while the y-axis shows mean HbA1c percentage. The graph depicts initial decreases in HbA1c for all groups, with Liraglutide 1.8 mg maintaining the lowest levels over time.*

FDA Label Image

Figure_4 (Figure 4)

Line graph showing mean HbA1c (%) over time (weeks) comparing Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Sitagliptin 100 mg. The graph indicates changes in HbA1c level across a 26-week period for these drug treatments.*

FDA Label Image

Figure-5 (Figure 5)

A Kaplan-Meier curve comparing the percentage of patients with an event over time between Liraglutide and placebo groups, measured in months from randomization. The graph shows a lower event rate in the Liraglutide group versus placebo. Patient numbers at risk at various time points are listed below the x-axis. Hazard ratio (HR) and confidence interval (CI) are noted on the graph.*

FDA Label Image

Pen_image (Image 01)

Liraglutide injection pen for subcutaneous use, labeled for single-patient use only. The pen is predominantly blue with a grey label area displaying the text 'Liraglutide injection' in white and a warning in red text. It is designed and distributed by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Injection-pen (Image 22)

Illustration of the Liraglutide Injection Pen components, including pen cap, rubber stopper, cartridge tip, cartridge with cartridge scale, dose display, dose selector with pointer, and dose button. The image also shows a flow check symbol related to the injection pen operation.*

FDA Label Image

Needle-example (Image 23)

An instructional illustration labeled "Needle (example)" showing four components from left to right: outer needle cap, inner needle cap, needle, and protective tab. Each component is labeled with blue text identifying its name.*

FDA Label Image

Triangle_1 (Image 24)

Liraglutide 6 mg/mL subcutaneous injection in a single-dose vial. The packaging is labeled by Teva Pharmaceuticals USA, Inc. The label includes dosage strength and identification information on a blue and white background with Teva branding.*

FDA Label Image

Triangle_2 (Image 25)

Liraglutide 6 mg/mL is a subcutaneous injection provided by Teva Pharmaceuticals USA, Inc. The vial depicted is a clear glass container with a grey rubber stopper and metal cap, labeled with the product name Liraglutide and strength 6 mg/mL. The vial is designed for human prescription use.*

FDA Label Image

Triangle_3 (Image 26)

FDA Label Image

Tirangle_4 (Image 27)

Liraglutide injection, 6 mg/mL, in a 3 mL single-dose vial. The vial label displays the proprietary name Liraglutide and the active ingredient liraglutide. The label includes dosing information and manufacturer's details, with Teva Pharmaceuticals USA, Inc. identified as the labeler. The product is intended for subcutaneous use.*

FDA Label Image

Triangle_5 (Image 28)

Liraglutide 6 mg/mL injection carton and vial label from Teva Pharmaceuticals USA, Inc. The package includes the proprietary name Liraglutide, active ingredient liraglutide, and indicates the subcutaneous injection dosage form. The vial is labeled with the same strength and manufacturer information.*

FDA Label Image

Triangle_6 (Image 29)

Packaging label for Liraglutide injection 6 mg/mL by Teva Pharmaceuticals USA, Inc. The label includes product name, active ingredient (liraglutide), dosage form (injection), strength (6 mg/mL), and administration route (subcutaneous). The design features blue and gray diagonal lines with white background and essential product information clearly displayed.*

FDA Label Image

Tirangle_7 (Image 30)

Liraglutide 6 mg/mL injection carton by Teva Pharmaceuticals USA, Inc. The packaging label shows the proprietary name "Liraglutide" prominently, along with the dosage strength of 6 mg/mL and the route of administration as subcutaneous injection. The label includes standard FDA required information and branding for this prescription drug product.*

FDA Label Image

Triangle_8 (Image 31)

Liraglutide 6 mg/mL injection carton label by Teva Pharmaceuticals USA, Inc. The label displays the drug name, strength, dosage form as subcutaneous injection, and quantity of 3 mL per container. The packaging includes branding and standard regulatory information.*

FDA Label Image

Image-a (Image 32)

An instructional illustration showing a user pulling back the blue handle of a pen injector device, likely preparing it for injection. The image focuses on the fingers gripping the device and the directional arrow indicating the pulling motion.*

FDA Label Image

Image-b (Image 33)

Illustration showing a close-up of a hand gripping a syringe injection device with an arrow indicating a twisting or unlocking motion. This image is part of an instructional diagram likely demonstrating the preparation or use of a subcutaneous injection device for liraglutide.*

FDA Label Image

Image-c (Image 34)

An instructional illustration showing a close-up of a person preparing a subcutaneous injection. The image depicts fingers holding the medication vial or cartridge and an arrow indicating the insertion or attachment of a component, likely the needle or syringe, to the medication device. This guide is likely part of usage instructions for liraglutide injection.*

FDA Label Image

Image-d (Image 35)

An instructional illustration shows a hand pulling a cap off the tip of a syringe or injection pen, indicated by an arrow pointing away from the device, demonstrating how to prepare the liraglutide subcutaneous injection for use.*

FDA Label Image

Image-e (Image 36)

An instructional illustration showing hands operating a liraglutide injection pen. The image highlights the 'flow check symbol' on the device, demonstrating how to select it before use.*

FDA Label Image

Image-f (Image 37)

Illustration showing a finger tapping or flicking the base of a prefilled injection pen, likely demonstrating an injection preparation or priming step for a subcutaneous injection device.*

FDA Label Image

Image-g (Image 38)

An instructional illustration showing a hand holding a liraglutide injection pen and the motion to remove the pen cap by pulling it straight off. A close-up inset highlights the pen's dosing window displaying '0 mg' and the pen's injection tip with a protective cover.*

FDA Label Image

Image-h (Image 39)

Illustration showing a close-up of a hand holding a Liraglutide injection pen, demonstrating the action of pressing or adjusting the dosing mechanism to administer the subcutaneous injection.*

FDA Label Image

Image-i (Image 40)

An instructional illustration showing a hand peeling back a cover from a syringe or injection pen. The image is labeled with the letter I in the top left corner, indicating a step in a multi-step process, likely for preparing or administering the liraglutide injection.*

FDA Label Image

Image-j (Image 41)

An instructional illustration showing a hand holding a syringe-like device, with the thumb pushing a plunger or button on the device, indicating a step in preparing or using the injection device for liraglutide subcutaneous injection.*

FDA Label Image

Image-k (Image 42)

An instructional illustration showing a hand pulling off the cap from the needle end of a prefilled injection pen. The image highlights removing the cap with an arrow indicating the direction to pull.*

FDA Label Image

Image-l (Image 43)

An instructional illustration showing hands adjusting the dose selector on a Liraglutide injection pen. The image highlights selection of doses 0.6 mg, 1.2 mg, and 1.8 mg, demonstrating how to rotate the dosage knob for subcutaneous injection.*

FDA Label Image

Image-m (Image 44)

An instructional illustration showing a hand pressing down on the top of a Liraglutide injection pen to administer the dose. The inset highlights the dose indicator on the pen displaying '0 mg', indicating completion or readiness of the dose.*

FDA Label Image

Image-n (Image 45)

An illustration showing a hand holding a liraglutide injection pen vertically with the needle pointing downward into a hand, accompanied by a stopwatch displaying 6, likely indicating an injection step or wait time during subcutaneous administration.*

FDA Label Image

Image-o (Image 46)

An instructional illustration showing the technique for subcutaneous injection with a syringe or pen device. The image depicts the needle being inserted at an angle into the skin, indicated by a large upward arrow suggesting the direction or motion of injection.*

FDA Label Image

Image-p (Image 47)

An instructional illustration showing the cap being removed from a syringe needle, likely for a subcutaneous injection. The syringe design and needle tip are clearly depicted, consistent with injectable medication administration.*

FDA Label Image

Image-q (Image 48)

An instructional illustration showing hands adjusting or preparing a liraglutide injection device. The image highlights a close-up of fingers manipulating the pen-type injector with an arrow indicating a movement direction, likely for dose setting or device activation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.